Advanced search×

Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.

Eur J Drug Metab Pharmacokinet 33(4):247-52 (2008) PMID 19230599

Allometric principles have been applied to scale and predict human pharmacokinetic parameters of irbesartan, an important AT1 receptor antagonist. The preclinical data gathered from rats, macaques (monkeys) and dogs were used in the allometric analysis. The use of these species was rationalized because preclinical models based on these species have been used in the evaluation pharmacodynamic activity of irbesartan. The human parameter values for clearance (CL/F), volume of distribution (V/F), and elimination rate constant (Kel) were scaled using simple allometry (CL/F, V/F and Kel) or with correction factors (CL/F). The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L). The present work presents an opportunity for prospective allometric scaling for the compounds belonging to this important therapeutic class.

Version: za2963e q8za8 q8zb8 q8zc3 q8zd7 q8ze1 q8zf3 q8zgd

Similar articles you may find interesting…

  1. Time of celebration of decades of excellence.

    Biomed Chromatogr 24(1):1 (2009) PMID 20017123

  2. Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retro...

    Arzneimittelforschung 60(1):12-21 (2010) PMID 20184222

    Retrospective evaluation of fluoxetine and norfluoxetine pharmacokinetic data demonstrated existence of both PM and EM phenotypes in the Indian population. Based on the overall data (n=144 subjects) there appeared to be 10.4% of PM phenotypes for fluoxetine and/or possibly for other polymorphic CYP2...
  3. Dear Dr. Walson

    Clin Ther 30(10):2 (2008) PMID 19014849